ClinicalTrials.gg
CompletedNCT04370002SENSCODEUpdated Nov 20, 2026

Sensor-based Characterization of Depression

An observational study in Unipolar Depression, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Massachusetts General Hospital · Observational

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
98
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 319 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.

Enrollment
25th of 40
98 · median 149
Started
2020
with 7 others
Observational
40 of 319
5 open now
Registered
222nd of 319
by date
Lead sponsor
8 of 319
Massachusetts General Hospital

Among the 319 studies in Depressive Disorder with a site in United States, this one is the 25th largest by enrollment of the 40 observational ones that give a count, is one of 8 that started in 2020, is one of 40 observational ones, and was the 222nd registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

38 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 319 studies in Depressive Disorder with a site in United States, or all of them as a file.
02

Study summary

This is a longitudinal study where individual with Major Depressive Disorder (MDD) will be monitored for 12 weeks. The study aims to develop an objective, sensor-based, algorithm able to detect the presence of depression as well as predict treatment response. Measurement-based treatment is considered optimal and the development of a valid passive, objective, behavioral and biological assessment of depressive symptoms that does not rely on clinician interviews will improve monitoring and ultimately improve treatment significantly.

Read the detailed description

In this longitudinal study 100 individuals with Major Depressive Disorder (MDD) will be monitored for 12 weeks. Data will include self-report surveys, in-person assessments, physiological features derived by wearable devices and socialization and activity data derived by mobile applications. The study will utilize advanced statistical methods to integrate different sources of passive sensor-based behavioral and physiological data to develop models able to detect depression and predict treatment response.

03

Conditions studied

  • Unipolar Depression

Keywords

  • Depression
  • Sensors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be individuals with Major Depressive Disorder

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (ages 18-75),
  2. Able to read, understand, and provide written in English,
  3. Meet criteria for a primary psychiatric diagnosis of current major depressive disorder
  4. Hamilton Depression Rating Scale (HDRS) total score ≥ 18,
  5. Must have measurable skin conductance/electrodermal activity (as assessed at the screening visit),
  6. Must own a working smartphone and use it regularly,
  7. Must own a windows PC (or tablet) or a Mac computer (or laptop),
  8. Must have access to Internet service every day.
  9. Must have started antidepressant medications, changed medication dosage, or started therapy within 3 weeks

Exclusion criteria

Exclusion Criteria:

  1. Active drug or alcohol use disorder in the past 3 months,
  2. History of psychotic disorder,
  3. History of mania or hypomania,
  4. Epilepsy or history of Seizure Disorder (including PNES), narcolepsy, Alzheimer Disease, Parkinson's Disease, ALS, Severe TBI, Dementia, MS, Cerebral Palsy, and Neuralgia.
  5. Untreated hypothyroidism,
  6. Unstable medical disease,
  7. Cognitive impairment that would impede adherence to study procedures,
  8. Acute suicide or homicide risk,
  9. Current treatment with electroconvulsive therapy, vagal nerve stimulation therapy, deep brain stimulation, transcranial magnetic stimulation therapy, or phototherapy,
  10. Cannot comprehend or communicate in English,
  11. Lack of working smartphone or lack of daily access to Internet service,
  12. Inability to measure skin conductance/electrodermal activity (as assessed at the screening visit), and
  13. Inability or unwilling to, at minimum, wear the physiological sensor (E4) wristbands, download monitoring apps, and fill out the surveys.
  14. Participants with more than two treatment failures (more than two adequate trials of meds on the basis of ATRQ) in the current mood episode.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
98 participants (actual)
Patient registry
No

Groups and cohorts

  • No Intervention

    This is an observational study. There is no active treatment that is examined.

06

What researchers measure

Primary outcomes

  1. The Hamilton Depression Rating Scale (HDRS) 17-items

    The HDRS-17 is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. Total score can range from 0 to 53.

    Time frame: Past week.

Secondary outcomes

  1. Patient Health Questionnaire 9 (PHQ-9)

    The PHQ-9 is a self-report questionnaire of depressive symptoms. Total scores can vary from 0 to 27. Higher scores indicate worse depressive symptoms.

    Time frame: Past 7 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in May 2024, 51 months.

Of 54 non-industry observational studies under Depressive Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 104. This study's 51 months is above that.

Counting every sponsor, half of 57 studies reached it within 38 months; a quarter within 21 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2024 → May 2024 and completion Nov 2024 → May 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2020
First posted
Apr 30, 2020
StartActual
Jan 28, 2020
Primary completionActual
May 17, 2024was Sep 2024
CompletionActual
May 17, 2024was Nov 2024
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Primary completion
Sep 1, 2024→May 17, 2024 (actual)
Nov 20, 2026
Study completion
Nov 30, 2024→May 17, 2024 (actual)
Nov 20, 2026
Enrollment
100 (estimated)→98 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    Primary completion Sep 1, 2024→May 17, 2024 (now actual)
    Study completion Nov 30, 2024→May 17, 2024 (now actual)
    Enrollment 100 (estimated)→98 (actual)
    + 3 other changes: responsible party, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04370002
Collaborators
Massachusetts Institute of Technology
Responsible party
Paola Pedrelli (Associate Professor, Massachusetts General Hospital) — Principal investigator
First posted
Apr 30, 2020
Start date
Jan 28, 2020
Primary completion
May 17, 2024
Completion
May 17, 2024
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion